Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 36

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 36
---
 Pre-Funded
Units and no exercise of the Series L Warrants and Placement Agent Warrants, and after deducting estimated placement agent fees and estimated
offering expenses payable by us, our as adjusted net tangible book value as of June 30, 2025 would have been approximately $23.39 million,
or $5.63 per Depositary Share. This represents an immediate decrease in net tangible book value of $7.19 per Depositary Share to
our existing shareholders and an immediate accretion of $0.54 per Depositary Share to investors purchasing Units in this offering.
The final public offering price will be determined through negotiation between us and the placement agent in the offering and may be at
a discount to the current market price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative
of the final public offering price.

The following table illustrates
this dilution on a per Depositary Share basis:

|                                                                                                                                      |     | As at June 30, 2025   |       |   |
|:-------------------------------------------------------------------------------------------------------------------------------------|:----|:----------------------|------:|:--|
|                                                                                                                                      |     | Per Depositary Shares |       |   |
| Assumed public offering price per Depositary Share                                                                                   |     | $                     |  5.09 |   |
| Historical net tangible book value per Depositary Share as of June 30, 2025                                                          |     | $                     | 12.82 |   |
| Decrease per Depositary Share attributable to pro forma adjustment                                                                   
 above                                                                                                                                |     | $                     | (0.62 | ) |
| Pro forma net tangible book value per Depositary Share as of June                                                                    
 30, 2025                                                                                                                             |     | $                     | 12.19 |   |
| Decrease to net tangible book value per Depositary Share attributable to investors purchasing our Depositary Shares in this offering |     | $                     | (6.56 | ) |
| As adjusted net tangible book value per Depositary Share as of June 30, 2025, after giving effect to this offering                   |     | $                     |  5.63 |   |
| Accretion per Depositary Share to the investors in this offering                                                                     |     | $                     |  0.54 |   |

A
$1.00 increase in the assumed combined public offering price of $5.09 per Unit would
increase the as adjusted net tangible book value